FDA clears Radiotherapy planning software:
This article was originally published in Clinica
Executive Summary
MDS Nordion's Helax-TMS V5.0 treatment planning software with segmented intensity modulated radiation therapy (IMRT) has received 510(k) clearance from the US FDA. The Canadian company's radiotherapy planning procedure is particularly effective for head, neck and prostate cancers which are difficult to treat with current technology without damaging surrounding healthy tissue. The software is able to do inverse planning, a tool provided to create plans intended for IMRT treatment delivery.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.